Dr Marc Ferrante (University Hospital Leuven, Leuven, Belgium) kindly took the time to speak with touchIMMUNOLOGY about the 52-week results from the phase 3 FORTIFY study investigating the efficacy and safety of risankizumab as a maintenance treatment in patients with Crohn’s disease.
His presentation entitled ‘EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN’S DISEASE: 52 WEEK RESULTS FROM THE PHASE 3 FORTIFY STUDY’ was given at UEG Week Virtual, 3-5 Oct 2021.
- The FORTIFY study builds on previous findings; what is currently known about the potential use of risankizumab in the treatment of Crohn’s disease? (0:17)
- What were the key findings of the FORTIFY maintenance study? (1:31)
- What is the potential role for maintenance therapy with risankizumab in clinical practice? (2:48)
Disclosures: Dr Marc Ferrante has received grants from Amgen, Biogen, Janssen, Pfizer and Takeda; personal fees from, Abbvie, Amgen, Biogen, Boehringer Ingelheim, Celltrion, Falk, Ferring, Janssen, Lamepro, Eli Lilly, Medtronic, MSD, Mylan, Pfizer, Sandoz, Takeda, Thermo Fisher and Truvion Healthcare and non-financial support from AbbVie, Amgen, Biogen, Boehringer-Ingelheim, Celltrion, Falk, Ferring, Janssen, Lamepro, Lilly, Medtronic, MSD, Mylan, Pfizer, Sandoz, Takeda, Thermo Fisher and Truvion Healthcare.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of UEG Week Virtual, 3-5 Oct 2021.
Share this Video
Related Videos In Inflammatory Bowel Disease
Detlef Schuppan, UEG 2021: Transglutaminase 2 Inhibitor in Celiac Disease
touchIMMUNOLOGY caught up with Prof. Detlef Schuppan (Mainz University Medical Center, Mainz, Germany) to talk about the results for the phase 2 study investigating the oral transglutaminase 2 inhibitor, ZED1227, in patients with celiac disease. His presentation entitled ‘ORAL INHIBITOR OF TISSUE TRANSGLUTAMINASE PREVENTS MUCOSAL DAMAGE IN CELIAC PATIENTS UNDERGOING GLUTEN CHALLENGE’ was given at […]
Detlef Schuppan, UEG 2021: Advances in the Management of Celiac Disease
It was a pleasure to catch up with Prof. Detlef Schuppan (Mainz University Medical Center, Mainz, Germany) following his presentations at virtual UEG week to discuss the current unmet needs in the treatment of celiac disease and advances being made in its management. His presentation entitled ‘ORAL INHIBITOR OF TISSUE TRANSGLUTAMINASE PREVENTS MUCOSAL DAMAGE IN […]
Marc Ferrante, UEG 2021: Filgotinib SELECTION Study Results in Ulcerative Colitis
touchIMMUNOLOGY were delighted to speak with Dr Marc Ferrante (University Hospital Leuven, Leuven, Belgium) about the results from the phase 2B/3 study of filgotinib in patients with ulcerative colitis as well as the use of the Partial Mayo Clinical Score in measuring outcomes. His presentation entitled ‘EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!